Reference Age (year)/sex PRP type Previous treatment CsA dosage and duration Clinical outcome
1
Current report
1.5/ F
III
Topical corticosteroid and tacrolimus 0.1% ointment
2.5 mg/kg 3 month
Complete clearance
2
Wetzig T. et al. 2003 17
4/ M
III
topical, low-potency corticosteroids and urea 10% ointment 3 mg/kg 18 weeks
Complete clearance
3
Chen et al. 2022 18
1.5/ M
III
low-potency corticosteroids and moisturizing cream
3 mg/kg 20 weeks
Complete clearance
4
Craigrow et al. 201819
1:3months/NR 2: 1month/ NR
CARD14-associated
MTX, etanercept, PUVA
NR
1: Partial 2: Partial
5
Signa et al. 201920
1: 7/ M 2: 7/ M
CARD14-associated
topical and systemic steroids, etanercept
1: 5mg/kg 3 month 2: 5mg/kg 3 month 1: Partial 2: Partial
6
Liang et al. 2020 22
7 / M
V
Corticosteroids, calcineurin inhibitors, MTX, acitretin, isotretinoin
75 mg 2 month
Ineffective
7
Maloney et al. 201726
4 / M
V
Acitretin, MTX
50 -125 mg 3 weeks
unknown
8
Lora et al. 201823
13 / M
III
Acitretin, MTX
3 mg/kg 4 weeks
Ineffective
9
Bonomo et al. 2018 24
7 / F
III
tacrolimus 0.1% ointment, triamcinolone 0.1% ointment
300 mg 5 month
Initially, it showed a good response, then CsA had to be discontinued due to a flare-up of symptoms and concerns about adverse effects
10
Kim et al. 2015 27
17 / M
III
oral steroids, phototherapy, acitretin
NR
Ineffective
11
Chiramel et al. 202021
7 / M
CARD14-associated
acitretin
3-4.5mg/kg 4 month
Partial